Compositions, methods and uses for dengue virus serotype-4 constructs

US9408901B2 · kind B2 · utility

Assignees

• Takeda Vaccines, Inc. · US
• The United States of America, as represented by the Secretary, Health and Human Services · US

Inventors

• Jill A. Livengood · Fort Collins, US
• Claire Y. Huang · Fort Collins, US
• Timothy D. Powell · Fort Collins, US
• Dan T. Stinchcomb · Boulder, US
• Jorge E. Osorio · Mount Horeb, US

Key dates

• Filing date: Nov 8, 2013
• Grant date: Aug 9, 2016
• Expiry date: Mar 3, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.